Protyon is a digital health venture specializing in oncology that supports clinical decision-making through advanced molecular modeling. By generating 3D digital models based on patient-specific cancer mutation genetic codes, the company predicts the effectiveness of targeted therapies. This enables clinicians to choose the best available treatment options, aiming to increase patient longevity and reduce healthcare costs by eliminating ineffective treatments. Additionally, Protyon offers educational courses for clinicians and computational prediction services for life science research partners to enhance precision medicine.